Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 20, Issue 9, 1998, Pages 739-742

  Guinan, P ^a   Shaw, M ^a   Mirochnik, Y ^a   Slobodskoy, L ^a   Ray, V ^a   Rubenstein, M ^a  

^a Hektoen Institute for Medical Research   (United States)

Author keywords

Chemotherapy; Paclitaxel; Prostate cancer; Thalidomide

Indexed keywords

PACLITAXEL; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; DISEASE MARKER; DRUG POTENCY; GROWTH INHIBITION; MALE; NONHUMAN; PROSTATE CANCER; RAT; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MALE; MICE; MICE, NUDE; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; THALIDOMIDE; TUMOR CELLS, CULTURED;

EID: 0032424025     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)